Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | PPOX | P50336 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7752178 | 0.93 | DTYMK (0.46) | DTYMKTDP1MEN1TTRPPOX | |
| SCHEMBL3902768 | 0.85 | DTYMK (0.51) | DTYMKTDP1MEN1TTRPPOX | |
| SCHEMBL405684 | 0.85 | DTYMK (0.51) | DTYMKTDP1MEN1KMT2ATSHR | |
| SCHEMBL29596737 | 0.84 | DTYMK (0.50) | DTYMKTDP1MEN1TTRPPOX | |
| SCHEMBL2894347 | 0.84 | DTYMK (0.50) | DTYMKTDP1MEN1TTRPPOX | |
| SCHEMBL2977714 | 0.84 | DTYMK (0.50) | DTYMKTDP1MEN1TTRPPOX | |
| SCHEMBL194902 | 0.81 | TDP1 (0.50) | TDP1MEN1KMT2AVCAM1MAPK1 | |
| SCHEMBL28135877 | 0.81 | TSHR (0.40) | VCAM1TSHR | |
| SCHEMBL15203579 | 0.81 | DTYMK (0.47) | DTYMKTDP1MEN1TTRKMT2A | |
| SCHEMBL11614707 | 0.81 | TSHR (0.49) | DTYMKTDP1MEN1TTRPPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| EP-3316884-A1 | THERAPEUTIC INHIBITORY COMPOUDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-05-09 | — | — | EP | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2017001924-A1 | THERAPEUTIC INHIBITORY COMPOUDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013161853-A1 | QUINAZOLINEDIONE DERIVATIVE | 中外製薬株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2003095417-A1 | PROCESS FOR THE MANUFACTURE OF 4-FLUORO-ANTHRANILIC ACID | MITENI S.P.A. (IT) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DTYMK 1672/4885TDP1 3331/4885MEN1 1423/4885 |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DTYMK 1672/4885TDP1 3331/4885MEN1 1423/4885 |
| US-10023557-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DTYMK 1672/4885TDP1 3331/4885MEN1 1423/4885 |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DTYMK 1672/4885TDP1 3331/4885MEN1 1423/4885 |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | PPARD, SLC5A2, PPARG | DTYMK 3793/4885TDP1 4283/4885MEN1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.